Clinical Edge Journal Scan

Higher sensitivity to contact allergens in children with atopic dermatitis


 

Key clinical point: Children with atopic dermatitis (AD) may have a higher sensitivity to contact allergens, such as fragrances and metals, than children without AD.

Major finding: Overall, 36.9% vs 26.4% of children with vs without AD presented with at least one positive patch test. Children with v. without AD showed a higher prevalence of ≥1 positive patch test for allergens, such as nickel sulfate, cobalt chloride, methylisothiazolinone, fragrance mix-2, potassium dichromate, fragrance mix-1, methylchloroisothiazolinone/methylisothiazolinone, and neomycin sulfate, with the prevalence difference being highest for fragrance mix-1 (5.8% vs 0.9%; P = .004293).

Study details: This retrospective study included 432 children aged 0-14 years with eczematous dermatitis who underwent patch testing, of which 23.8% of children were diagnosed with AD.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Bonamonte D et al. Contact allergy in children with and without atopic dermatitis: An Italian multicentre study. Contact Dermatitis. 2022 (Apr 21). Doi: 10.1111/cod.14130

Recommended Reading

Atopic dermatitis: Ruxolitinib well-tolerated and effective under maximum use conditions
MDedge Dermatology
Dupilumab holds potential for treating hand eczema in moderate-to-severe atopic dermatitis
MDedge Dermatology
Atopic dermatitis: Abrocitinib shows quick response in difficult-to-treat anatomical regions
MDedge Dermatology
Upadacitinib earns FDA approval for ankylosing spondylitis 
MDedge Dermatology
Clinical Edge Journal Scan Commentary: Atopic Dermatitis May 2022
MDedge Dermatology
Steroid phobia drives weaker prescribing, nonadherence for AD
MDedge Dermatology
Moderate-to-severe atopic dermatitis: Abrocitinib shows promise in patients who switch from dupilumab
MDedge Dermatology
Atopic dermatitis: Higher threshold efficacy response and QoL benefits with abrocitinib
MDedge Dermatology
Atopic dermatitis: Baricitinib+TCS shows promise in patients with inadequate response to CyA
MDedge Dermatology
Atopic dermatitis: Dupilumab shows potential as a long-term, continuous treatment option
MDedge Dermatology